GlassScriptPhysician profile
Michelle A Parra
NPI 1679805048
$4,409.96
in general payments reported to CMS, 2019-2025
21 companies · $685 in 2025
The $685 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $1,470 · 2023: $1,226 · 2024: $752 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,507 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,506.51 |
| Education | $156.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $890.55 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $579.88 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $410.83 | 2021-2025 | |
| Alkermes, INC. | $387.38 | 2022-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $293.03 | 2023-2025 | Uzedy, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $288.42 | 2022-2025 | Caplyta |
| Lundbeck LLC | $287.99 | 2022-2025 | Rexulti, Abilify Maintena |
| Otsuka America Pharmaceutical, INC. | $232.95 | 2022-2023 | Rexulti |
| Corium, LLC | $220.70 | 2023-2025 | Azstarys |
| Neurocrine Biosciences, INC. | $174.43 | 2022-2025 | Ingrezza |
| Indivior INC. | $104.20 | 2023-2025 | Perseris, Sublocade |
| Biogen, INC. | $93.54 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $88.88 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $69.34 | 2023-2024 | Trintellix |
| Tris Pharma INC | $66.11 | 2022-2025 | Dyanavel Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $63.37 | 2023-2025 | Spravato, Invega, Invega Trinza |
| Axsome Therapeutics, INC. | $56.40 | 2023 | Auvelity |
| Gilead Sciences, INC. | $39.88 | 2023-2024 | |
| Ironshore Pharmaceuticals INC. | $24.27 | 2024 | |
| Neos Therapeutics, LP | $20.87 | 2023 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $16.94 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Parra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.